title: Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
authors.affiliation: Oncopharmacology Unit, Centre Antoine-Lacassagne, Nice, France.
authors.forename: Gérard
authors.initials: G
authors.lastname: Milano
authors.affiliation: Biostatistics Unit, Centre Antoine-Lacassagne, Nice, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Chamorey
authors.affiliation: Medical Oncology Unit, Centre Antoine-Lacassagne, Nice, France.
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Ferrero
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000009:adverse effects*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013318:Stroke Volume / Q000187:drug effects*; D000068878:Trastuzumab / Q000009:adverse effects*; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D014408:Biomarkers, Tumor; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab